Clinical stage pharmaceutical Company Theralase Technologies Inc. (TSX-V: TLT, OTCQB: TLTFF, Forum) said on Monday its sixth patient to be treated in the Phase Ib of its Non-Muscle Invasive Bladder Cancer Clinical Study has demonstrated no tumour recurrence, progression or presence of the disease at the 540 day clinical and cystoscopy assessment.
More information can be found here.
Theralase was in the news recently when it granted an aggregate of 12,340,000 stock options. The company also said it has been very successful in executing on strategic objectives.
Full Disclosure: Theralase Technologies Inc. is a client of Stockhouse Publishing.